Epizyme, Inc. has achieved a preclinical milestone in its alliance with Eisai Co., Ltd., triggering a $4 million milestone payment. The companies entered a worldwide strategic alliance in March 2011 to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients. In total, Epizyme is eligible for more than $200 million in R&D and sales milestones, as well as double-digit royalties. Addi...